HIPOS-ER (HYPOGLYCEMIA IN PORTUGAL OBSERVATIONAL STUDY – EMERGENCY ROOM)- OUTCOMES WITH DIFFERENT ANTI-HYPERGLYCEMIC AGENTS
Author(s)
Conceição J1, Laires P1, Dores J2, Araújo F3, Carr R4, Brodovicz K5, Radican L6, Vicente V7, Nogueira AM1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital de Santo António, Porto, Portugal, 3Hospital Beatriz Ângelo, Loures, Portugal, 4Merck Sharp & Dohme, Ballerup, Denmark, 5Merck & Co., North Wales, PA, USA, 6Merck & Co., Inc., Whitehouse Station, NJ, USA, 7Eurotrials, Lisbon, Portugal
OBJECTIVES: HIPOS-ER is an observational study to describe the patient population of Type 2 Diabetics treated with an anti-hyperglycemic agent (AHA) and admitted to the emergency room (ER) with a hypoglycemic event. In this analysis we aim to describe the hypoglycemia events by AHA class. METHODS: The study enrolled patients from 7 centers in mainland Portugal from Jan 2013 – Jan 2014. Sociodemographic and clinical data were collected at the emergency room and patients who required hospital admission were followed up. Episodes were enrolled consecutively within the sampling period. AHA therapy classes were Insulin - Group 1, secretagogue based - Group 2, oral AHA excluding secretagogue - Group 3 and Insulin+secretagogue – Group 4. RESULTS: A total of 238 patients were admitted to the ER with severe hypoglycemia and 105 (44%) were hospitalized. The distribution based on AHA therapy: 55% (131) Group 1, 32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. Previous severe hypoglycemia in the last 12 months was more frequent in Group 1 vs. Group 2 (p=0.009). Group 2 patients were more often followed up in Primary Care vs. Group 1 (84% vs.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PDB1
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Diabetes/Endocrine/Metabolic Disorders